Sarepta Therapeutics Inc Wholesale Acquisition Cost Or Gross Price Of Gene Therapy Elevidys For Duchenne Muscular Dystrophy Is $3.2M
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics announced the wholesale acquisition cost or gross price of its gene therapy Elevidys for Duchenne Muscular Dystrophy at $3.2 million.
June 22, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepta Therapeutics' Elevidys gene therapy for Duchenne Muscular Dystrophy has a wholesale acquisition cost of $3.2 million.
The announcement of the wholesale acquisition cost for Elevidys at $3.2 million indicates the company's confidence in the value of its gene therapy. This could lead to increased revenues and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100